The Neural-Interface Review Grinds On, And So Does The Waiting

GENEVA — The safety review of Somaform Augmetics' neural-interface line remains exactly where it has been for months: open, contested, and conclusive about nothing. Regulators under the Concordat framework have neither cleared the line nor pulled it, and the deadlock has a human shape in the clinics of Geneva, where prospective recipients wait on a decision that keeps not arriving. Augmented humans now number past five percent of the population, and the interface question sits at the frontier of that growth. Somaform founder Julian Morrow, an augmentation-rights advocate, argued this week that "delay is not caution, it is a decision to make people wait for a benefit the evidence supports." Reviewers counter, off the record, that the evidence is precisely what remains incomplete. Caught between is Lena Kovač, a Ljubljana translator whose degenerative nerve condition the interface might ease: "I am told to be patient by people whose hands still work," she said. The review will continue. So, for her, will the waiting — the one variable no ruling has moved.